Fulcrum Therapeutics Future Growth
Future criteria checks 2/6
Fulcrum Therapeutics is forecast to grow earnings and revenue by 26.8% and 49.5% per annum respectively while EPS is expected to grow by 38.5% per annum.
Key information
26.8%
Earnings growth rate
38.5%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | 49.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 13 Mar 2024 |
Recent future growth updates
Recent updates
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11Industry Analysts Just Upgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Revenue Forecasts By 83%
May 12We're Hopeful That Fulcrum Therapeutics (NASDAQ:FULC) Will Use Its Cash Wisely
May 07Fulcrum Therapeutics beats on revenue
May 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 49 | -98 | -77 | -23 | 4 |
| 12/31/2025 | 12 | -117 | -99 | -101 | 8 |
| 12/31/2024 | 2 | -113 | -100 | -92 | 8 |
| 12/31/2023 | 3 | -97 | -91 | -91 | N/A |
| 9/30/2023 | 3 | -99 | -88 | -88 | N/A |
| 6/30/2023 | 3 | -98 | -93 | -92 | N/A |
| 3/31/2023 | 4 | -109 | -101 | -99 | N/A |
| 12/31/2022 | 6 | -110 | -99 | -97 | N/A |
| 9/30/2022 | 11 | -107 | -102 | -99 | N/A |
| 6/30/2022 | 14 | -104 | -96 | -94 | N/A |
| 3/31/2022 | 17 | -90 | -86 | -84 | N/A |
| 12/31/2021 | 19 | -81 | -80 | -78 | N/A |
| 9/30/2021 | 18 | -75 | -78 | -76 | N/A |
| 6/30/2021 | 15 | -73 | -60 | -58 | N/A |
| 3/31/2021 | 13 | -69 | -56 | -55 | N/A |
| 12/31/2020 | 9 | -71 | -55 | -54 | N/A |
| 9/30/2020 | 5 | -69 | -39 | -38 | N/A |
| 6/30/2020 | 3 | -68 | -48 | -47 | N/A |
| 3/31/2020 | 1 | -68 | -46 | -45 | N/A |
| 12/31/2019 | N/A | -90 | -40 | -39 | N/A |
| 9/30/2019 | N/A | -85 | -46 | -41 | N/A |
| 6/30/2019 | N/A | -79 | -38 | -32 | N/A |
| 3/31/2019 | N/A | -71 | -34 | -26 | N/A |
| 12/31/2018 | N/A | -39 | -32 | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FULC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FULC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FULC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FULC's revenue (49.5% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: FULC's revenue (49.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FULC's Return on Equity is forecast to be high in 3 years time